Poll results: Medical education falters on pain relief

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain.

A significant number of ONI readers believe that their medical training in pain relief and opioid pharmacology is inadequate to help them meet the needs of their cancer patients with pain. Of those who responded to ONI’s June poll question-“Do you feel your medical school education in pain relief and opioid pharmacology was adequate?”-71% answered in the negative. Only 14% said that their pain management training was adequate, while 16% said they weren’t sure.

Although the International Association for the Study of Pain has established guidelines for pain management, compliance is spotty, said Kathleen M. Foley, MD, of Memorial Sloan-Kettering Cancer Center, in New York.

The poll was linked to the article, “US cancer patients still plagued by undertreated pain” (June 2008, page 20). To respond to this month’s poll (on page 2), visit www.CancerNetwork.com.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content